Literature DB >> 30542047

Differences in the actions of adrenaline and noradrenaline with regard to glucose intolerance in patients with pheochromocytoma.

Ichiro Abe1, Hideyuki Fujii1, Hanako Ohishi1, Kaoru Sugimoto1, Midori Minezaki1, Midori Nakagawa1, Saori Takahara1, Tadachika Kudo1, Makiko Abe2,3, Kenji Ohe4, Toshihiko Yanase5, Kunihisa Kobayashi1.   

Abstract

Glucose intolerance is often observed in patients with pheochromocytoma. However, it remains controversial issue that glucose intolerance on pheochromocytoma is caused by impaired insulin secretion and/or by increased insulin resistance. We aimed to reveal the mechanism of glucose intolerance on pheochromocytoma with regard to the type and amount of catecholamines released. We evaluated 12 individuals diagnosed with pheochromocytoma and who underwent surgery to remove it. We examined glycemic parameters before and after surgery and investigated the association between the change of parameters of insulin secretion (homeostasis model assessment of β-cell function (HOMA-β)), insulin resistance (homeostasis model assessment of insulin resistance (HOMA-IR)) and that of urinary levels of metanephrine/normetanephrine before and after surgery. Overall, fasting plasma glucose, glycated hemoglobin (HbA1c), HOMA-β, and HOMA-IR were improved significantly after surgery. Regression analysis showed that the improvement in HOMA-β from before to after surgery was significantly positively associated with an improvement in urinary levels of metanephrine from before to after surgery and showed a significantly negative association with improvement in urinary levels of normetanephrine from before to after surgery. The improvement in HOMA-IR from before to after surgery was significantly positively associated with an improvement in urinary levels of normetanephrine from before to after surgery. Our results showed that pheochromocytoma extirpation improved glycemic parameters. Furthermore, the different effects elicited by excess amounts of adrenaline and noradrenaline on glucose intolerance were demonstrated.

Entities:  

Keywords:  Glucose intolerance; Insulin resistance; Insulin secretion; Pheochromocytoma

Mesh:

Substances:

Year:  2018        PMID: 30542047     DOI: 10.1507/endocrj.EJ18-0407

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  5 in total

Review 1.  Potential Therapeutic Targeting Neurotransmitter Receptors in Diabetes.

Authors:  Xiaohui Pan; Shibing Tao; Nanwei Tong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-20       Impact factor: 6.055

2.  VEGF-A/VEGF-B/VEGF-C expressions in non-hereditary, non-metastatic phaeochromocytoma.

Authors:  Ichiro Abe; Farhadul Islam; Chung Yau Lo; Victor Liew; Suja Pillai; Alfred K Lam
Journal:  Histol Histopathol       Date:  2021-03-18       Impact factor: 2.303

3.  Correlation Between Plasma Catecholamines, Weight, and Diabetes in Pheochromocytoma and Paraganglioma.

Authors:  Lauren N Krumeich; Andrew J Cucchiara; Katherine L Nathanson; Rachel R Kelz; Lauren Fishbein; Douglas L Fraker; Robert E Roses; Debbie L Cohen; Heather Wachtel
Journal:  J Clin Endocrinol Metab       Date:  2021-09-27       Impact factor: 6.134

4.  Association between higher urinary normetanephrine and insulin resistance in a Japanese population.

Authors:  Masaya Murabayashi; Makoto Daimon; Hiroshi Murakami; Tomoyuki Fujita; Eri Sato; Jutaro Tanabe; Yuki Matsuhashi; Shinobu Takayasu; Miyuki Yanagimachi; Ken Terui; Kazunori Kageyama; Itoyo Tokuda; Kaori Sawada; Kazushige Ihara
Journal:  PLoS One       Date:  2020-02-13       Impact factor: 3.240

Review 5.  Glucose Intolerance on Phaeochromocytoma and Paraganglioma-The Current Understanding and Clinical Perspectives.

Authors:  Ichiro Abe; Farhadul Islam; Alfred King-Yin Lam
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-26       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.